Adhesin Genes and Serum Resistance in Haemophilus Influenzae Type F Isolates
Overview
Authors
Affiliations
The incidence of invasive infections due to Haemophilus influenzae has decreased significantly in developed countries with high rates of vaccination against H. influenzae serotype b (Hib). This vaccine provides no protection against H. influenzae serotype f (Hif), typically associated with invasive infections in adults with chronic disease and/or immunodeficiency, and rarely in otherwise healthy adults and children. The specific properties of Hif associated with virulence remain largely uncharacterized. A panel of 26 Hif strains consisting of both invasive disease-associated and mucosal surface non-invasive disease-associated isolates was surveyed by DNA fingerprinting, biotyping and PCR detection of hmw1, hmw2, hsf, the hif fimbrial locus and the lipo-oligosaccharide (LOS) biosynthetic island, and assessment of β-lactamase expression and determination of resistance to the bactericidal activity of normal adult human serum. Repetitive sequence-based PCR fingerprinting differentiated the 26 strains into three clusters, with the majority of isolates (22/26, 84.6 %) clustered into a single indistinguishable group. Most isolates (24/26, 92.3 %) were of biotype I and two isolates produced β-lactamase with detection of a conjugative plasmid, and the isolates displayed a range of resistances to the bactericidal activity of human serum. All 26 isolates carried the adhesin hsf, 21 carried a partial hif fimbrial operon and 4 had the adhesin genes hmw1/2. A LOS biosynthetic island was detected in 20 isolates consisting of the genes lic2BC. It was concluded that Hif has many recognized virulence properties and comprises a relatively homogeneous group independent of the anatomical source from which it was isolated.
Xiao J, Su L, Huang S, Liu L, Ali K, Chen Z Infect Drug Resist. 2023; 16:5359-5373.
PMID: 37605758 PMC: 10440118. DOI: 10.2147/IDR.S424468.
Immunogenicity of trimeric autotransporter adhesins and their potential as vaccine targets.
Thibau A, Dichter A, Vaca D, Linke D, Goldman A, Kempf V Med Microbiol Immunol. 2019; 209(3):243-263.
PMID: 31788746 PMC: 7247748. DOI: 10.1007/s00430-019-00649-y.
Atack J, Winter L, Jurcisek J, Bakaletz L, Barenkamp S, Jennings M J Infect Dis. 2015; 212(4):645-53.
PMID: 25712964 PMC: 4539897. DOI: 10.1093/infdis/jiv103.
Singh B, Su Y, Al-Jubair T, Mukherjee O, Hallstrom T, Morgelin M Infect Immun. 2014; 82(6):2378-89.
PMID: 24664511 PMC: 4019195. DOI: 10.1128/IAI.01636-13.
Su Y, Resman F, Horhold F, Riesbeck K BMC Genomics. 2014; 15:38.
PMID: 24438474 PMC: 3928620. DOI: 10.1186/1471-2164-15-38.